Citadel Advisors
BDSX icon

Citadel Advisors’s Biodesix BDSX Stock Holding History

Citadel Advisors’s Portfolio BDSX Stock Details BDSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,275
Closed -$41K – 12569
2025
Q1 		$41K Sell
3,275
-13,840
-81% -$266K ﹤0.01% 12521
2024
Q4 		$524K Buy
17,115
+16,985
+13,065% +$500K ﹤0.01% 8452
2024
Q3 		$4.63K Buy
130
+105
+420% +$3.61K ﹤0.01% 13554
2024
Q2 		$765 Buy
+25
New +$714 ﹤0.01% 13919
2024
Q1 		– Sell
-40
Closed -$1.47K – 14557
2023
Q4 		$1.47K Sell
40
-75
-65% -$2.35K ﹤0.01% 13818
2023
Q3 		$3.79K Buy
+115
New +$3.19K ﹤0.01% 13548
2023
Q1 		– Sell
-45
Closed -$2.07K – 14708
2022
Q4 		$2.07K Sell
45
-1,700
-97% -$46.2K ﹤0.01% 14382
2022
Q3 		$44K Sell
1,745
-1,685
-49% -$65K ﹤0.01% 11718
2022
Q2 		$113K Buy
+3,430
New +$112K ﹤0.01% 11295

Other funds holding BDSX

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
TAM
Telemark Asset Management Boston, Massachusetts $1.08B AUM 70.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

Citadel Advisors's BDSX Position: Q1 2026 in Review

Citadel Advisors sold out of Biodesix (BDSX) in Q1 2026, closing a stake of 25,985 shares — an estimated $177K sold.

Citadel Advisors first reported a position in BDSX in Q4 2020 and held it in 16 quarters. The position peaked at $915K in Q1 2021. 40 funds tracked by Wall St. Rank hold BDSX as of Q1 2026.

  • Citadel Advisors reported no remaining Biodesix position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 25,985 Biodesix shares in Q1 2026, an estimated $177K.
  • Citadel Advisors first reported a position in Biodesix in Q4 2020 and held it in 16 quarters.
  • Citadel Advisors's Biodesix position peaked at $915K in Q1 2021.
  • 40 funds tracked by Wall St. Rank held Biodesix as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.